Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia
NCT ID: NCT00254202
Last Updated: 2024-12-13
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
593 participants
INTERVENTIONAL
2005-11-18
2007-03-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Iloperidone is being development as a treatment for symptoms of schizophrenia. This trial will test the safety and efficacy of iloperidone in patients with an acute exacerbation of the disease.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Iloperidone
Oral iloperidone
Iloperidone
Ziprasidone
Oral ziprasidone
Ziprasidone
Placebo
Oral placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Iloperidone
Ziprasidone
Placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* PANSS-T of at least 70 at screening and baseline
Exclusion Criteria
* DSM-IV diagnosis of psychiatric disorder other than schizophrenia
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vanda Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vanda Investigational Site
Little Rock, Arkansas, United States
Vanda Investigational Site
Anaheim, California, United States
Vanda Investigational Site
Cerritos, California, United States
Vanda Investigational Site
Garden Grove, California, United States
Vanda Investigational Site
Glendale, California, United States
Vanda Investigational Site
Los Angeles, California, United States
Vanda Investigational Site
National City, California, United States
Vanda Investigational Site
Oceanside, California, United States
Vanda Investigational Site
Paramount, California, United States
Vanda Investigational Site
Pico Rivera, California, United States
Vanda Investigational Site
San Diego, California, United States
Vanda Investigational Site
San Diego, California, United States
Vanda Investigational Site
San Diego, California, United States
Vanda Investigational Site
Santa Ana, California, United States
Vanda Investigational Site
Upland, California, United States
Vanda Investigational Site
Bradenton, Florida, United States
Vanda Investigational Site
Fort Lauderdale, Florida, United States
Vanda Investigational Site
Maitland, Florida, United States
Vanda Investigational Site
Atlanta, Georgia, United States
Vanda Investigational Site
Augusta, Georgia, United States
Vanda Investigational Site
Hoffman Estates, Illinois, United States
Vanda Investigational Site
Lake Charles, Louisiana, United States
Vanda Investigational Site
Rockville, Maryland, United States
Vanda Investigational Site
Saint Charles, Missouri, United States
Vanda Investigational Site
St Louis, Missouri, United States
Vanda Investigational Site
Clementon, New Jersey, United States
Vanda Investigational Site
Brooklyn, New York, United States
Vanda Investigational Site
Cincinnati, Ohio, United States
Vanda Investigational Site
Philadelphia, Pennsylvania, United States
Vanda Investigational Site
Austin, Texas, United States
Vanda Investigational Site
Houston, Texas, United States
Vanda Investigational Site
Irving, Texas, United States
Vanda Investigational Site
Richmond, Virginia, United States
Vanda Investigational Site
Tirupati, Andhra Pradesh, India
Vanda Investigational Site
Ahmedabad, Gujarat, India
Vanda Investigational Site
Manipal, Karnataka, India
Vanda Investigational Site
Aurangabad, Maharashtra, India
Vanda Investigational Site
Pune, Maharashtra, India
Vanda Investigational Site
Jaipur, Rajasthan, India
Vanda Investgational Site
Chennai, Tamil Nadu, India
Vanda Investigational Site
Lucknow, Uttar Pradesh, India
Vanda Investigational Site
Chinawaltair, Visakha Patnam, India
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Volpi S, Potkin SG, Malhotra AK, Licamele L, Lavedan C. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J Clin Psychiatry. 2009 Jun;70(6):801-9. doi: 10.4088/jcp.08m04391.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VP-VYV-683-3101
Identifier Type: -
Identifier Source: org_study_id